Chairman of the Board of Directors
Pierre A. MORGON is CEO of MRGN Advisors, Executive Vice President, Portfolio Strategy and Supranational Affairs at CanSino Biologics and Regional Partner for Switzerland at Merieux Equity Partners.
He is Chairman of the Boards of Theradiag, Eurocine Vaccines, MYCB1, Adiposs, Kupando and Health Technologies Holding, as well as Non-Executive Director to the Boards of Vaccitech, Univercells, Amoeba and Limula.
Pierre has over 35 years of experience in the global life science industry, especially with specialty care, vaccines and immunotherapy, at the helm of international operations, in C-level positions at global level in multinational corporations and as CEO of start-up companies.
He is a lecturer in several MBA programs and in life science conferences, and at the Mass Challenge incubator in Switzerland where he is also a mentor for start-up life sciences companies.
He holds a Doctorate of Pharmacy, a Master in Business Law and a MBA, and he is an alumnus of INSEAD and IMD.
Larry ABENSUR holds an engineering degree from the Ecole Nationale Supérieure de Chimie de Paris and an MBA from INSEAD. For 9 years, he held various marketing positions in the pharmaceutical industry as Product Manager for Human Biosynthetic Insulin at Eli Lilly, then at UPJOHN France as Marketing Manager. He then became General Manager of PBS Orgenics, an in vitro diagnostics company, for 6 years, until the merger with Self Care (INVERNESS) and the listing on Nasdaq.
In 1993 and 1994, Mr ABENSUR co-founded successively All Diag and Dectra Pharm. In 2005, Larry ABENSUR participated in the creation of Biosynex, which he co-managed until October 2010. Since June 2015, Larry ABENSUR is at the initiative of the creation of the BIOSYNEX group, a leading medtech in rapid diagnostic tests (RDT), where he holds the position of Chairman and CEO.
After a first and second cycle in pharmaceutical studies at the University of Paris V, Thierry PAPER completed an MBA at the Ecole Nationale des Ponts et Chaussées. He also holds a D.E.S. in medical biology from the University of Paris V. Thierry PAPER was an intern in Pharmacy until May 1990. He first joined the Israeli company Orgenics, where he held the positions of project manager and then marketing manager. Between 1993 and 1997, he was in charge of the development of the French company Matara. From 1997 to 2005, he was deputy director of the medical analysis laboratory J-P Accary. He has also been the manager of Axodev, a business development services company for the in vitro diagnostics industry, since 1997.
In 2005, Thierry PAPER took part in the creation of Biosynex, where he is the general and operational manager. In June 2015, he became Managing Director of the BIOSYNEX group.
Jacques AZANCOT is a graduate engineer from the Ecole Centrale de Paris. For more than 30 years, he has held general management positions in high-tech companies specialising in the design and production of special equipment and in the robotisation of industrial processes. For the past five years, he has been running AZALEE Consulting, a company he founded and whose vocation is to assist company managers and private equity funds in their investment or external growth strategy.
As an independent director, Jacques AZANCOT has been a member of the Supervisory Boards or Strategic Committees of diversified SMEs in the food industry, aeronautical subcontracting, building components, medical equipment and industrial tools.